Thierry Abribat
Amministratore Delegato presso Millendo Therapeutics SAS
Posizioni attive di Thierry Abribat
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Millendo Therapeutics SAS
 Millendo Therapeutics SAS Medical SpecialtiesHealth Technology Millendo Therapeutics SAS provides pharmaceutical research services. It engages in the development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The company was founded by Thierry Abribat, André de Villers, Ezio Ghigo and Aart Jan van der Lely on April 23, 2007 and is headquartered in Ecully, France. | Amministratore Delegato | 08/09/2009 | - |
| Fondatore | 08/09/2009 | - | |
| Presidente | 08/09/2009 | - | |
Amolyt Pharma SAS
 Amolyt Pharma SAS Pharmaceuticals: MajorHealth Technology Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France. | Direttore/Membro del Consiglio | 30/07/2014 | - |
| Amministratore Delegato | 30/07/2014 | - | |
| Fondatore | 30/07/2014 | - |
Storia della carriera di Thierry Abribat
Precedenti posizioni note di Thierry Abribat
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
EUSA Pharma SAS
 EUSA Pharma SAS BiotechnologyHealth Technology EUSA Pharma SAS specializes in pharmaceutical research for rare diseases. The company was founded by Gilles Alberici on September 24, 1999 and is headquartered in Limonest, France. | Amministratore Delegato | 01/01/2005 | 01/01/2007 |
Millendo Therapeutics US, Inc.
 Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | Direttore/Membro del Consiglio | 20/12/2017 | - |
| THERATECHNOLOGIES INC. | Direttore Tecnico/Scientifico/R&S | - | - |
| SANOFI | Direttore Tecnico/Scientifico/R&S | - | - |
Formazione di Thierry Abribat
| Institut National Polytechnique de Toulouse | Doctorate Degree |
Statistiche
Distribuzione geografica
| Francia | 6 |
| Canada | 2 |
| Stati Uniti | 2 |
Posizioni
| Chief Executive Officer | 3 |
| Founder | 2 |
| Chief Tech/Sci/R&D Officer | 2 |
Settori
| Health Technology | 7 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| SANOFI | Health Technology |
| THERATECHNOLOGIES INC. | Health Technology |
| Aziende private | 4 |
|---|---|
Millendo Therapeutics SAS
Millendo Therapeutics SAS Medical SpecialtiesHealth Technology Millendo Therapeutics SAS provides pharmaceutical research services. It engages in the development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The company was founded by Thierry Abribat, André de Villers, Ezio Ghigo and Aart Jan van der Lely on April 23, 2007 and is headquartered in Ecully, France. | Health Technology |
EUSA Pharma SAS
EUSA Pharma SAS BiotechnologyHealth Technology EUSA Pharma SAS specializes in pharmaceutical research for rare diseases. The company was founded by Gilles Alberici on September 24, 1999 and is headquartered in Limonest, France. | Health Technology |
Amolyt Pharma SAS
Amolyt Pharma SAS Pharmaceuticals: MajorHealth Technology Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France. | Health Technology |
Millendo Therapeutics US, Inc.
Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | Health Technology |
- Borsa valori
- Insiders
- Thierry Abribat
- Esperienza
